Valuation : Roche Holding AG

Market Cap 282B 349B 300B 257B 483B 33,179B 487B 3,341B 1,300B 16,825B 1,309B 1,281B 55,708B P/E 2026 *
19.7x
P/E 2027 * 17.4x
Enterprise Value 293B 362B 312B 267B 502B 34,458B 506B 3,469B 1,350B 17,473B 1,360B 1,330B 57,855B EV / Sales 2026 *
4.67x
EV / Sales 2027 * 4.37x
Free-Float
88.78%
Yield 2026 *
2.83%
Yield 2027 * 2.9%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 349B
+0.94%-4.88%+59.62%+110.64% 1,031B
+0.84%-1.84%+50.57%+67.07% 641B
+1.12%-2.10%+22.78%+75.58% 453B
-1.74%-6.05%+33.74%+33.69% 349B
+5.91%+3.49%+29.19%+46.88% 290B
-0.18%-0.92%+1.25%+12.53% 252B
+0.74%-1.69%+51.53%+69.37% 232B
+0.53%-1.52%-19.28%-53.74% 201B
+0.83%-0.42%+31.43%+93.27% 181B
Average +0.75%-3.00%+28.98%+50.59% 403.31B
Weighted average by Cap. +0.72%-3.99%+38.17%+66.68%

Financials

2026 *2027 *
Net sales 62.64B 77.49B 66.72B 57.18B 107B 7,373B 108B 742B 289B 3,739B 291B 285B 12,379B 65.47B 80.98B 69.73B 59.76B 112B 7,706B 113B 776B 302B 3,907B 304B 297B 12,938B
Net income 14.51B 17.94B 15.45B 13.24B 24.88B 1,707B 25.05B 172B 66.88B 866B 67.37B 65.91B 2,867B 16.33B 20.2B 17.39B 14.91B 28.01B 1,922B 28.21B 194B 75.3B 975B 75.85B 74.2B 3,227B
Net Debt 10.87B 13.44B 11.57B 9.92B 18.63B 1,279B 18.77B 129B 50.1B 649B 50.47B 49.37B 2,147B 4.02B 4.97B 4.28B 3.67B 6.89B 473B 6.94B 47.63B 18.53B 240B 18.67B 18.26B 794B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA